A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-cell Non-Hodgkin Lymphoma (NHL)
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Anti CD19 chimeric antigen receptor T cell therapy Cellular Biomedicine Group (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cellular Biomedicine Group
- 18 Dec 2017 Planned End Date changed from 1 Jun 2019 to 1 Aug 2019.
- 18 Dec 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2018.
- 18 Dec 2017 Planned initiation date changed from 1 Oct 2017 to 1 Dec 2017.